ZyVersa Therapeutics, Inc.
ZVSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,177 | $878 | $14,244 | $160,327 |
| - Cash | $1,531 | $3,138 | $5,902 | $329 |
| + Debt | $0 | $9 | $109 | $9,152 |
| Enterprise Value | -$354 | -$2,251 | $8,451 | $169,150 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$7 | -$10 | -$10 | -$10 |
| % Margin | – | – | – | – |
| EBITDA | -$9,136,834 | -$107,743 | -$14,430 | -$7,252 |
| % Margin | – | – | – | – |
| Net Income | -$9,413,435 | -$98,298 | -$14,048 | -$8,084 |
| % Margin | – | – | – | – |
| EPS Diluted | -8.48 | -1,089.66 | -930.25 | -173.66 |
| % Growth | 99.2% | -17.1% | -435.7% | – |
| Operating Cash Flow | -$7,560 | -$8,721 | -$4,889 | -$5,076 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$7,560 | -$8,721 | -$1,495 | -$5,076 |